Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.

Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR.

Cancer Immunol Immunother. 2006 Jul;55(7):761-74.

PMID:
16187086
2.

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1997 Aug;3(8):1277-88.

3.

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95.

PMID:
8877722
4.

Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.

Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J.

Clin Cancer Res. 1997 Jan;3(1):17-24.

5.

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, et al.

Cancer Res. 1990 Dec 1;50(23):7490-5.

6.

Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

Sondel PM, Hank JA.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Review.

PMID:
9457407
7.

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17.

PMID:
8811495
8.

A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.

Sosman JA, Kefer C, Fisher RI, Jacobs CD, Pumfery P, Ellis TM.

J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):171-80.

PMID:
7613643
9.

Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.

Bukowski RM, Murthy SA, Finke J, Caulfield MJ, Tubbs R, Herzog P, Stanley J, Edinger M, Tuason L, McLain D, et al.

J Immunother Emphasis Tumor Immunol. 1994 May;15(4):273-82.

PMID:
8061900
10.

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA.

Blood. 1995 Nov 1;86(9):3287-94.

11.

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41.

PMID:
7804528
12.

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

Redman BG, Flaherty L, Chou TH, Nakeff A, Pillote K, Kaplan J.

J Immunother (1991). 1991 Apr;10(2):147-51.

PMID:
2043595
13.

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.

Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, Ben-Bassat H, Biran S, Schlesinger M, Franks CR, et al.

Immunol Lett. 1992 Jul;33(2):127-34.

PMID:
1446917
14.

Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J, Kedar E.

Cancer Immunol Immunother. 1992;35(2):135-44.

PMID:
1596937
15.

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA.

Cancer Immunol Immunother. 1998 Aug;46(6):318-26.

PMID:
9756416
16.

Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.

Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP.

Med Oncol. 1998 Sep;15(3):191-8.

PMID:
9819796
17.

Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.

Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH.

J Natl Cancer Inst. 1990 Aug 15;82(16):1345-9.

PMID:
2199682
18.

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

Harel W, Shau H, Hadley CG, Morgan AC Jr, Reisfeld RA, Cheresh DA, Mitchell MS.

Cancer Res. 1990 Oct 1;50(19):6311-5.

19.

Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma.

Creagan ET, Rowland KM Jr, Suman VJ, Kardinal CG, Marschke RF Jr, Marks RS, Maples WJ.

Am J Clin Oncol. 1997 Oct;20(5):490-2.

PMID:
9345334
Items per page

Supplemental Content

Support Center